Back to discover
Disease

Meningococcal Infections

Late-stage therapeutic developmentEmerging research
MeSHMeningococcal Infections
1
Publications
8
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

6 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
8
All trials
2
Active
8
Late-stage
6
Completed
Late-stage studies

Multicenter, Randomized, Subject/Evaluator Blind, Active Control, Phase II/III Clinical Trial to Assess Immunogenicity and Safety of EG-MCV4 Meningococcal (Groups A, C, W-135, and Y) Conjugated Vaccines

Phase 2/3 · Recruiting · EyeGene Inc.

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV: A Single Center, Non-blinded, Randomized Clinical Trial

Phase 4 · Recruiting · Thomas Benfield

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Phase 3 · Completed · Sanofi Pasteur, a Sanofi Company

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as Toddlers

Phase 3 · Completed · Sanofi Pasteur, a Sanofi Company

Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure

Phase 4 · Completed · UCSF Benioff Children's Hospital Oakland

A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers

Phase 3 · Completed · Novartis Vaccines
Recently completed

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Phase 3 · Completed · Sanofi Pasteur, a Sanofi Company

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as Toddlers

Phase 3 · Completed · Sanofi Pasteur, a Sanofi Company

Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure

Phase 4 · Completed · UCSF Benioff Children's Hospital Oakland

A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers

Phase 3 · Completed · Novartis Vaccines

A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life

Phase 4 · Completed · Public Health England

A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age

Phase 3 · Completed · Novartis Vaccines

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes2
  • Disease Outbreaks1
  • Meningococcal Infections1
Leading journals1
  • BMC public health1
Leading researchers4
  • Giles LC1
  • Marshall HS1
  • Milazzo A1
  • Morello BR1
Affiliations (unnormalised)3
  • Adelaide Medical School1
  • Robinson Research Institute1
  • School of Public Health1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infections with bacteria of the species NEISSERIA MENINGITIDIS.

Identifiers
MeSHMeningococcal Infections
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.